02 Feb 2021 – Destiny Pharma to join panel discussion at the 7th Annual LSX World Congress 2021

Destiny Pharma PLC
(“Destiny” or “the Company”)

Destiny Pharma to Participate in Panel Discussion at the 7th Annual LSX World Congress 2021

Brighton, UK, 2 February 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that Neil Clark, Chief Executive Officer, will be taking part in a panel discussion at the 7th Annual LSX World Congress to be held virtually between 1-5 February, 2021.

The panel discussion ‘Investing In Infectious Disease – How Will The Covid Pandemic Transform The Development, Commercialisation, And Partnering Landscape?’ will be held at 15:00 GMT on 2nd February 2021.

The panel will be made available through the conference website and will be available to registered participants throughout the event – www.lsxleaders.com/lsx-world-congress.

– Ends –

Enquiries:

Destiny Pharma plc
Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)
+44 (0) 1273 704 440

finnCap Limited – Nominated Adviser and Joint Broker
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)
+44 (0) 20 7220 0500

WG Partners LLP – Joint Broker
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
+44 (0) 20 3705 9330

Optimum Strategic Communication
Mary Clark / Shabnam Bashir / Manel Mateus
+44 (0) 203 174 1789

About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.